Windtree Hosting Key Opinion Leader Webinar on Istaroxime for the Treatment of Acute Heart Failure and the Upcoming Data in Early Cardiogenic Shock

Additionally, Windtree will discuss its development program for istaroxime in early cardiogenic shock, which is currently in a Phase 2 study with targeted completion in Q4 2021.